

Claims

1. Formed particles comprising amoxicillin and clavulanic acid, wherein the particles are obtained by wet granulation.
2. The formed particles according to Claim 1, wherein amoxicillin is present in the form of amoxicillin trihydrate and clavulanic acid is present in the form of potassium clavulanate.
3. The formed particles according to Claim 1, wherein the ratio of amoxicillin to clavulanic acid is from 1:1 to 30:1.
4. The formed particles according to Claims 1 and 3, wherein the ratio of amoxicillin to clavulanic acid is 4:1, 7:1, 8:1, 12:1, 16:1, 20:1.
5. The formed particles according to Claim 1, further comprising excipients selected from fillers, binders, disintegrants, glidants, lubricants.
6. The formed particles of Claim 1, wherein the solvent used in the wet granulation is an organic solvent.
7. The formed particles according to Claims 1 and 6, wherein the organic solvent is acetone.
8. The formed particles according to Claim 1, wherein a binder dispersion in an organic solvent is used in wet granulation.

9. The formed particles according to claim 1 and 8, wherein the binder is hydroxypropyl cellulose and/or polyvinylpyrrolidone.
10. The formed particles according to Claim 1, which further comprise excipients that increase the absorption of amoxicillin.
11. The formed particles according to Claims 1 and 10, wherein the excipients that increase the absorption of amoxicillin are selected from the group of sodium deoxycholate, sodium docusate and sodium lauryl sulfate.
12. The formed particles according to Claim 1, which are irregular in shape or spherical.
13. The formed particles according to Claim 1, which are coated or uncoated.
14. A pharmaceutical composition comprising the formed particles according to Claim 1.
15. The pharmaceutical composition according to Claim 14, wherein the formed particles are irregular-shaped.
16. The pharmaceutical composition according to Claim 14, wherein the formed particles are spherical.
17. The pharmaceutical composition according to Claim 14 in the form of a multiple unit formulation.
18. The pharmaceutical composition according to Claim 14 in the form of a tablet, capsule or sachet.

19. The pharmaceutical composition according to Claim 14, which comprise excipients that increase the absorption of amoxicillin.
20. The pharmaceutical composition according to Claim 14 and 19, wherein the excipients that increase the absorption of amoxicillin are selected from the group of sodium deoxycholate, sodium docusate and sodium lauryl sulfate.
21. The pharmaceutical composition according to Claim 14, which has a coating.
22. A process for the preparation of the formed particles according to Claim 1 comprising the following steps:
 - preparation of the mixture of amoxicillin trihydrate and potassium clavulanate and excipients (with or without a binder),
 - wet granulation with an organic solvent or wet granulation with a binder dispersion in an organic solvent,
 - drying of particles,
 - grinding or sieving of dry particles,
 - optionally application of a coating
23. A process for the preparation of the formed particles according to Claim 1 comprising the following steps:
 - preparation of the mixture of amoxicillin trihydrate and potassium clavulanate and excipients (with or without a binder),
 - wet granulation with an organic solvent or wet granulation with a binder dispersion in an organic solvent,
 - extrusion of a wet mixture through a screen,
 - spheronization,
 - drying of particles,
 - optionally application of a coating

24. The procedure for the preparation of the formed particles according to Claims 22 and 23, wherein the organic solvent is acetone.